The US Supreme Court ruled Tuesday that generic drug makers can challenge big-name pharmaceutical firms in court to stop them from broadening the scope of their patent descriptions.
Apr 18, 2012
0
0
It's no secret that drug prices are increasing, but to what extent are rising costs explained by the advent of newer, better drugs? A study from the University of Pittsburgh found that new drugs entering the market do drive ...
Jan 7, 2019
1
242
(AP) -- Federal health officials on Monday approved the first generic versions of the blockbuster drug Zyprexa, an expensive treatment for schizophrenia and bipolar mood disorder.
Oct 24, 2011
0
0
Patient access to generic prescription drugs and community pharmacies are both increasingly at risk due to inadequate reimbursement rates that fail to cover the cost of filling prescriptions, according to a new survey of ...
Apr 8, 2015
0
13
(HealthDay) -- The Israeli drug maker Teva Pharmaceuticals has gained the first U.S. approval to market generic Lexapro (escitalopram) to treat depression and general anxiety disorder, the U.S. Food and Drug Administration ...
Mar 14, 2012
0
0
There is no difference between brand-name and generic drug formulations of amiodarone -- taken to control arrhythmia – in the incidence of thyroid dysfunction, according to a study in CMAJ (Canadian Medical Association ...
Jul 11, 2011
0
0
(AP) -- In a case that could affect India's role as drug provider to the developing world, the Supreme Court began hearing arguments Tuesday over whether the government had the right to deny a patent to Swiss drugmaker Novartis ...
Sep 6, 2011
0
0
Three South Korean pharmaceutical firms will soon be allowed to produce generic versions of the anti-impotence drug Viagra despite a row over patents, officials said Wednesday.
Mar 14, 2012
0
0
In what has the potential to significantly change how Corona patients are being treated and the severity of the disease, research spearheaded at Jerusalem's Hebrew University gathered early clinical evidence demonstrating ...
Dec 22, 2020
0
6
Mylan will pay $465 million to resolve accusations from some regulators that it overbilled the federal Medicaid program for the EpiPen allergy medication, the drugmaker announced Friday.
Oct 7, 2016
0
5
